Keywords: b-ms, extends, otsuka, abilify, deal, 400m, upfront

B-MS extends Otsuka Abilify deal for $400M upfront; accords for Sprycell and Exempra

Article | 06 April 2009

Print This

US drug major Bristol-Myers Squibb has extended its agreement with Japan\'s Otsuka Pharmaceutical for US rights for the development ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in